ONTOGENETIC MARKET ANALYSIS

Ontogenetic Market, By Light Equipment (Laser and Light-emitting Diode (LED)), By Actuator (Channelrhodopsin, Halorhodopsin, and Archaerhodopsin), By Sensor (Calcium (Aequorin, Cameleon, and Other Calcium Sensors), Chloride (Clomeleon), Membrane-gated (Mermaid), and Other Sensors), By Application (Neuroscience, Behavioral, Tracking, Retinal Disease Treatment, and Other Applications), and By Geography (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published In : Jan 2023
Code : CMI5474
Pages :172
Formats :
Excel and PDF
Industry : Medical Devices

Market News

Global Ontogenetic Market: Key Developments

In September 2021, Novartis acquires Arctos Medical, expanding optogenetics portfolio to bring gene therapies to patients with severe vision loss.

In May 2021, GenSight Biologics completed the PIONEER Phase I/II clinical trial of GS030. It combines gene therapy and optogenetics to treat Retinitis Pigmentosa (RP). Such studies increase the demand for optogenetic products/equipment.

In January 2021, SYMBXX initiated clinical trials in Adelaide, Australia, and Canada to develop laser light therapies to reduce the debilitating symptoms of Parkinson's disease.

In October 2020, Novartis AG announced the acquisition of Vedere Bio, adding novel optogenetic gene therapy technology for treating blindness.